Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer

Medical Science Monitor

Volumn 15, Issue 4, 2009, Pages

  Eichbaum, Michael H R ^a   Weiss, Luise M E ^a   Bruckner, Thomas ^a   Schneeweiss, Andreas ^a   Sinn, Hans Peter ^a   Gebauer, Gerhard ^a   Fersis, Nikos ^a   Kussmaul, Julia ^a   Sohn, Christof ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anemia; Carboplatin; Hemoglobin; Ovarian cancer; Taxane

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; HEMOGLOBIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; DRUG DOSE REDUCTION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TAXOIDS; YOUNG ADULT;

EID: 65949122316     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. American Cancer Society 2003. What are the key statistics about ovarian cancer ? (Available from: URL: http://www.cancer.org/docroot/CRI/content/CRI-2- 4-IX-What-are-the-key-statistics-for-ovarian-cancer-33.asp?sitearea=)
2. Reed NS, Sadozye AH: Role of chemotherapy in the management of epithelial ovarian cancer. Expert Rev Anticancer Ther, 2005; 5: 139-147
3. Kaye SB: Intravenous chemotherapy for ovarian cancer - the state of the art ? Int J Gynecol Cancer, 2000; 10(S1): 19-25 (Pubitemid 30220624)
4. McGuire III WP, Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer, 2003; 98(Suppl.3): S3-S8
5. du Bois A, Lück H, Meier W et al: A randomized clinical trial of cisplatin/paclitaxel vs carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst, 2003; 95: 1320-1329
6. Vermorken JB: The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. Int J Gynecol Cancer, 2001; 11(Suppl.1): 21-30
7. Katsumata N: Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer, 2003; 89(Suppl.3): S9-15
8. Vasey PA: Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol, 2003; 21: 136-144
9. Colombo N, Pecorelli S: What have we learned from ICON1 and ACTION ? Int J Gynecol Cancer, 2003; 13(Suppl.2): 140-143
10. Bamias A, Papadimitriou C, Efstahiou E et al. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer, 2006; 6: 288 (Pubitemid 44541830)
11. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Nat Cancer Inst, 1999; 91: 1616-1634
12. Vasey PA, Jayson GC, Gordon A et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer. J Natl Cancer Inst, 2004; 96: 1682-1691
13. Coiffier B, Guastalla JP, Pujade-Lauraine E et al: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer, 2001; 37: 1617-1623
14. Knight K, Walde S, Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med, 2004; 116(Suppl.7A): 11S-26S
15. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol, 1998; 25: 43-46
16. Crawford J, Cella D, Cleeland CS et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 2002; 95: 888-895
17. Caro JJ, Salas M, Ward A et al: Anemia as independent prognostic factor for survival in patients with cancer. Cancer, 2001; 91: 2214-2221
18. Alici S, Kaya S, Izmirli M et al: Analysis of survival factors in patients with advanced stage gastric adenocarcinoma. Med Sci Monit, 2006; 12(5): CR221-29
19. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol, 2003; 47: 1-11
20. Obermair A, Cheuk R, Horwood K et al: Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. Cancer, 2001; 92: 903-908
21. Münstedt K, Kvacic M, Zygmunt M et al: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol, 2003; 23: 837-843
22. Obermair A, Handisurya A, Kaider A et al: The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer, 1998; 83: 726-731
23. Obermair A, Petru E, Windbichler G et al: Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep, 2000; 7(3): 639-644
24. Gadducci A, Sartori E, Landoni F et al: Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. Gynecol Oncol, 2005; 98: 118-123
25. Di Maio M, Pisano C, Tambaro R et al. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Front Biosci, 2006; 11: 1585-1590 (Pubitemid 43253444)
26. WHO Classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs, FA Tavassoli, P Devilee, IARC Press, 2003
27. Skirnisdottir I, Sorbe B: Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO stages III-IV) epithelial ovarian cancer. Int J Oncol, 2007; 30: 727-734
28. Skirnisdottir I, Sorbe B: Survival and prognostic factors in early-stage epithelial ovarian cancer treated with taxane-based adjuvant chemotherapy. Int J Gynecol Cancer, 2007; 17: 1231-1237
29. Höckel M, Vaupel P: Biological consequences of tumour hypoxia. Semin Oncol, 2001; 28(Suppl.8): 36-41
30. Acker T, Plate KH: Role of hypoxia in tumour angiogenesis-molecular and cellular angiogenic crostalk. Cell Tissue Res, 2003; 314: 145-155
31. Varlotto J, Stevenson MA: Anemia, tumour hypoxemia and the cancer patient. Int J Radiation Oncology Biol Phys, 2005; 63: 25-36 (Pubitemid 41583539)
32. Horiuchi A, Imai T, Shimizu M, Oka K et al: Hypoxia-induced changes in the expression of VEGF, HIF-1alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res, 2002; 22: 2697-2702 (Pubitemid 36069300)
33. Birner P, Schindl M, Obermair A et al: Expression of hypoxia-inducible factor 1α in epithelial ovarian tumours: its impact on prognosis and on response to chemotherapy. Clin Cancer Res, 2001; 7: 1661-1668
34. Zhu G, Saed GM, Deppe G et al: Hypoxin up-regulates the effects of prostaglandin E2 on tumour angiogenesis in ovarian cancer cells. Gynecol Oncol, 2004; 94: 422-426
35. Mukhopadhyay D, Datta K: Multiple regulatory pathways of vascular permeability factor/ vascular endothelial growth factor (VPF/VEGF) expression in tumours. Semin Cancer Biol, 2004; 14
36. Wang Y, Pankulu RI, Tsao W et al: Bimodal effect pf hypoxia in cancer: role of hypoxia inducible factor in apoptosis. Mol Pharm, 2004; 1: 156-165
37. Imai T, Horiuchi A, Wang C et al: Hypoxia attenuates the expression of E-Cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol, 2003; 163: 1437-1447
38. Eltabbakh GH, Belinson JL, Kennedy AW et al: p53 overexpression is nt an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer, 1997; 80: 892-898
39. Nielsen JS, Jakobsen E, Holund B et al: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer, 2004; 14: 1086-1096 (Pubitemid 39603351)
40. Ceccaroni M, Chieco P, Alboni C et al. p53 expression, DNA ploidy and mitotic index as prognostic factors in patients with epithelial ovarian carcinoma. Tumori, 2004; 90: 600-606 (Pubitemid 40288345)
41. Dogan E, Saygili U, Tuna B et al: p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol, 2005; 97: 46-52
42. Donnelly ET, Kelley M, Rockwell S: Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumour cells in vitro and in vivo. Cancer Chemother Pharmacol, 2004; 53: 43-50 (Pubitemid 38161188)
43. Teicher A, Ara G, Herbst R et al: PEG-hemoglobin: effects on tumour oxygenation and response to chemotherapy. In vivo, 1997; 11: 301-311 (Pubitemid 27404243)
44. Silver DF, Piver MS: Effects of recombinant human erythropoetin on the antitumour effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol, 1999; 73: 280-284
45. Skvortsova I, Skvortsov S, Haidenberger A et al: Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother, 2004; 16: 372-380 (Pubitemid 39049888)
46. Safra T, Groshen S, Jeffers S et al: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer, 2001; 91: 90-100
47. Buyse M, Molenberghs G, Burzykowski T et al: The validation of surrogate endpoints in meta-analyses of randomised experiments. Biostatistics, 2000; 1: 49-67
48. The International Collaborators in Ovarian Neoplasm (ICON)/ AGO-OVAR. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR 2.2 trial. Lancet, 2003; 361: 2099-2106